Laboratory Corporation of America ® Holdings (LabCorp ®) (NYSE: LH) today announced results for the quarter ended September 30, 2013.
Third Quarter Results
Net earnings were $148.3 million and earnings per diluted share (EPS) were $1.63 in the third quarter of 2013. Non-GAAP earnings per diluted share, excluding amortization, restructuring and other special charges recorded in the third quarter of 2013 and 2012 (Adjusted EPS Excluding Amortization) were $1.80 and $1.76, respectively.
Revenues for the quarter were $1,462.2 million, an increase of 3.0% over the third quarter of 2012. Testing volume, measured by requisitions, increased 5.1% and revenue per requisition decreased 1.9%. Revenue per requisition decreased year over year due largely to previously-discussed government payment reductions, payment issues related to molecular pathology codes and strong growth in the Company’s toxicology business.Operating income for the quarter was $244.6 million. Non-GAAP operating income excluding restructuring and other special charges recorded in the quarter (Adjusted Operating Income) was $248.3 million, or 17.0% of revenue. Margins were negatively affected by the factors noted above. Operating cash flow for the quarter was $234.2 million, compared to $203.8 million in 2012. The balance of cash at the end of the quarter was $174.1 million, and there were $372.0 million of borrowings outstanding under the Company’s $1 billion revolving credit facility. During the quarter, the Company repurchased $288.0 million of stock, representing 2.9 million shares. As of September 30, 2013, $304.1 million of repurchase authorization remained under the Company’s previously approved share repurchase plan. The Company announced that its Board authorized an additional $1 billion share repurchase program. This authorization clearly demonstrates the Company’s continued commitment to return capital to and create value for shareholders. The Company recorded restructuring and other special charges of $3.7 million during the third quarter of 2013. During the third quarter of 2013, the Company received cash proceeds of $7.5 million and recorded a net gain of $5.5 million on the sale of an investment. The investment was one of several strategic investments the Company has made in the area of diagnostic technology.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV